Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected ...

J.P. Morgan analysts said it was too early to discuss the financial impact of the recall, but estimated that $70 million to ...

SightMD proudly announces that Dr. Jeffrey Martin is one of the first ophthalmologists on Long Island to implant the revolutionary Clareon PanOptix Pro, the latest multifocal intraocular lens (IOL) ...

Gain insights into RxSight's Q1 2025 earnings highlights, revised guidance, market challenges, and growth strategies.

Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients ...

Phakic IOL technologies have undergone substantial improvements in recent years, with progressive upgrades in design and material and more accurate sizing strategies.At the ESCRS winter meeting, Erik ...

RxSight (RXST) stock plunged 28% as the MedTech firm cut full-year guidance and issued disappointing early Q1 results, citing ...

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high ...

The global implantable collamer lens market is set to experience remarkable expansion in the coming decade, driven by the increasing adoption of minimally invasive vision correction procedures. Market ...

Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Bausch + Lomb (NYSE ...